Reinigung und Charakterisierung einer lysosomalen Phospholipase A1 aus Makrophagen

Makrophagen sind professionelle phagozytische Zellen, welche körpereigene gealterte oder toten Zellen und in den Körper eingedrungene Krankheitserreger aufnehmen. Die phagozytierten Partikel werden von lysosomalen Hydrolasen abgebaut und daraus hervorgehende Antigene an Zellen des spezifischen Immunsystems präsentiert. Aufgabe der lysosomalen Phospholipase A1 (PLA1) ist der Abbau von Phospholipiden. Sie spielt damit nicht nur eine elementare Rolle bei dem Abbau von Phospholipidmembranen nach Phago- und Autophagozytose, sondern kann auch an der Generation von Lipidantigenen beteiligt sein. Die vorliegende Arbeit bietet zum ersten Mal Hinweise auf die Sequenz der lysosomalen PLA1. Mittels proteinbiochemischer Reinigung und nachfolgender massenspektrometrischer Sequenzanalyse wurden zwei Proteinkandidaten identifiziert, welche der lysosomalen PLA1-Aktivität zugrunde liegen können. Des Weiteren werden ausführliche Untersuchungen zu den Katalyseeigenschaften des Enzyms an Liposomen präsentiert. Die Lipidzusammensetzung der Membran beeinflusst maßgeblich die Aktivität der lysosomalen PLA1. So haben in die Membran integrierte anionische Phospholipide eine stark enzymaktivierende Wirkung. Eine Erhöhung der Ionenstärke oder des pH-Wertes vermindern die Bindungsfähigkeit der lysosomalen PLA1 an die Membran und damit deren Aktivität. Dies lässt vermuten, dass elektrostatische Wechselwirkungen eine Rolle bei der Membranbindung spielen. Das Enzym besitzt pIsMacrophages are professional phagocytes which engulf and degrade senescent and dead cells as well as pathogens. Phagocytosed particles are subsequently degraded by lysosomal enzymes. The lysosomal phospholipase A1 (PLA1) degrades phospholipids, the major components of biological membranes and, hence, plays a mandatory role in decomposition of phagocytosed and autophagocytosed membranes. Furthermore the enzyme might play a role in the processing of lipid antigens for immune presentation. Nevertheless, the gene encoding this important enzyme activity is as yet unknown. Here, we used proteinbiochemical methods to isolate the lysosomal PLA1 activity from RAW B cells and identified resulting sequences by tandem mass spectrometry. This analysis revealed for the first time two putative protein candidates responsible for lysosomal PLA1 activity. Using native enzyme fractions and liposome-embedded substrate, we show that PLA1 activity depends on the presence of anionic phospholipids, low pH and low ionic strength. Lysosomal PLA1 only attaches to membranes with anionic but not zwitterionic charges. High ionic strength impairs binding demonstrating that electrostatic attraction is responsible for membrane partitioning. Upon binding the enzyme remains on membranes for numerous catalytic cycles. The enzyme’s pIs a

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Background: Breast cancer and its treatments are associated with a detrimental effect on bone health. Here we report the results of an exploratory analysis assessing changes in levels of biomarkers of bone metabolism in patients enrolled in the phase IIIb 4EVER study. Methods: The 4EVER trial investigated everolimus in combination with exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer. In this prespecified exploratory analysis, changes in biomarkers of bone turnover were assessed in patients from baseline to weeks 4, 12, and 24. The serum bone markers assessed were procollagen type 1 N-terminal propeptide (P1NP), C-terminal cross-linking telopeptide of type 1 collagen (CTX), osteocalcin, parathyroid hormone (PTH), and 25-hydroxyvitamin D (25-OH-vitamin D). On-treatment changes in bone markers over time were described per subgroup of interest and efficacy outcomes. Results: Bone marker data were available for 241 of 299 enrolled patients. At the final assessment, P1NP, osteocalcin, PTH, 25-OH-vitamin D (all P < 0.001), and CTX (P = 0.036) were significantly decreased from baseline values per the Wilcoxon signed-rank test. At the last assessment (24 weeks or earlier), levels of serum CTX and PTH were significantly lower (P = 0.009 and P = 0.034, respectively) among patients with vs. without prior antiresorptive treatment (ART). Serum CTX levels were significantly lower (P < 0.001), and 25-OH-vitamin D concentrations significantly higher (P = 0.029), at the last postbaseline assessment in patients receiving concomitant ART vs. those without ART. Changes from baseline in PTH and 25-OH-vitamin D concentrations to the final assessment were significantly smaller in patients with prior ART. Lower baseline serum concentrations of osteocalcin and PTH were associated with clinical response (partial vs. non-response) at 24 weeks. High serum levels of CTX and P1NP at baseline were risk factors for progression at 12 weeks. Conclusions: These exploratory analyses support use of everolimus plus exemestane for the treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer, and add to the body of evidence suggesting a potentially favorable impact of everolimus on bone turnover. Trial registration: NCT01626222. Registered 22 June 2012, https://clinicaltrials.gov/ct2/show/NCT01626222. Keywords: Bone health, Bone marker, Breast cancer, Everolimus, Hormone receptor-positive, Mammalian target of rapamyci